SPY295.44+0.56 0.19%
DIA244.88-0.14 -0.06%
IXIC9,324.59+39.71 0.43%

Oppenheimer Maintains Perform on Nektar Therapeutics, Raises Price Target to $25

Oppenheimer maintains Nektar Therapeutics (NASDAQ:NKTR) with a Perform and raises the price target from $24 to $25.

Benzinga · 05/18/2020 12:23

Oppenheimer maintains Nektar Therapeutics (NASDAQ:NKTR) with a Perform and raises the price target from $24 to $25.